글로벌 성장 호르몬 장애 치료 시장 – 2030년까지의 산업 동향 및 예측

성장 호르몬 장애 치료 시장 분석 및 규모

미국 소아과 학회에 따르면, 인간의 성장 호르몬 결핍증은 드문 질환이며 미국에서 3,000명 중 1명에서 10,000명 중 1명 미만에게 영향을 미칩니다. 인간 성장 호르몬 약물은 오늘날 시장에서 광범위하게 이용 가능하여 건강상의 이점에 대한 인식을 형성하고 있으며, 이는 여러 제조 회사의 수익 창출에 기여합니다. 이러한 약물에 대한 수요는 성장 호르몬 질환의 비율을 증가시키고 있습니다.

Data Bridge Market Research는 2023-2030년 예측 기간 동안 글로벌 성장 호르몬 장애 치료 시장의 성장률을 분석합니다. 글로벌 성장 호르몬 장애 치료 시장의 예상 CAGR은 언급된 예측 기간 동안 약 9.11%인 경향이 있습니다. 시장은 2022년에 5,538.85백만 달러로 평가되었으며 2030년까지 11,125.92백만 달러까지 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

성장 호르몬 장애 치료 시장 범위 및 세분화

Market Definition

Growth hormone disorder is a rare type of condition that is typically characterized by inadequate secretion of growth hormone (GH) from the anterior pituitary gland. This kind of hormones can be present since birth and cause serious genetic mutation or structural defects in the brain. The growth hormone disorders can be acquired in the later years due to the presence of severe infection, trauma among others. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy.

Global Growth Hormone Disorder Treatment Market Dynamics

Drivers

• Increasing Trend of urban lifestyle

Urban lifestyles and deteriorating food habits are projected to increase the demand for human growth hormone drugs and diverse treatment facilities. There has been an increase in stress and sleeplessness because of the hectic life patterns of the citizens working in cities. This is causing huge hormonal imbalance in the body. Medication growth hormones help in such situations and thus are becoming more popular among youngsters and old people around the world.

• Increase in Growth Disorders

There has been a continuing increase in public understanding regarding the use of synthetic growth hormone therapy. The expanding industrial research for the causes of growth disorders, along with an improving incidence of diagnosis, led to an increase in market growth. Many growth-related issues such as adult growth hormone deficiency, pediatric growth hormone deficit, idiopathic low stature, and hereditary illnesses such as Turner syndrome and Prader-Willi syndrome are contributing enough to boost the market size. Globally, 1 in 3800 children suffers from a growth hormone deficit. Turner syndrome affects about 1 in every 2000 females, and Prader-Willi syndrome affects 1 in every 30,000 persons. Thus, it boosts the market growth.

Opportunities

• Increased Clinical Studies and Related Activities

Robust product pipeline and wide R&D activities for the development of novel growth hormone therapies are projected to be the major factors pushing the market growth. For instance, in September 2018, Novo Nordisk presented Phase II clinical trial data of its investigational GH therapy, Somapacitan, that is specified for the treatment of pediatric growth hormone deficiency. In addition to this, in May 2019, Ascendis Pharma A/S published results from the Phase III clinical trial of its TransCon hGH, that is indicated for pediatric growth hormone deficiency.

• Growing Government Initiatives

The various initiatives taken by numerous government and private organizations to spread awareness about growth hormone deficiencies and human growth hormone treatment are projected to drive the market. Each year, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), which is a U.S.-based nonprofit charitable organization, celebrates International Children’s Growth Awareness Day to spread awareness about the diagnosis and treatment of growth hormone disorders to initiate fast recovery among humans, particularly children.

 Restraints/Challenges

• Risk of Complications

The growth hormone disorder treatment market has a high risk of complications. Complications such as the possible side effects of growth hormone therapy which include knee, hip, or other joint pain; allergic reactions, such as rash, swelling, or hives, and an increase in blood sugar levels are witnessed post the therapy. Thus, it hampers the market growth.

• High Cost

The huge expenditure associated with these drugs hamper the market growth. The growth hormone disorder drugs cost high and thus sometimes becomes unaffordable for the lower economic groups.

This global growth hormone disorder treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global growth hormone disorder treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Growth Hormone Disorder Treatment Market          

COVID-19 left a major impact on almost every business sector and in turn is hampering the pharmaceutical sector as well. Human growth hormone injections dipped considerably during the pandemic year starting in March 2020. COVID-19 left a negative impact on the global growth hormone disorder treatment market. In the post-pandemic era, there was an increasing demand for human growth hormone treatment and drugs because of patients' vulnerability to getting infected by the virus. Furthermore, a report published by the magazine frontier stated that patients suffering from Prader-Willi syndrome may get late onset symptoms after getting infected positively increased the demand for human growth hormone therapy in the U.S. and beyond.

Recent Developments:

• In February 2021, Pfizer and OPKO health Inc. announced that the European Medicines Agency had approved Somatrogon for treating juvenile growth hormone deficient patients.
• In August 2021, Ascendis Pharma received FDA approval for their SKYTROFA injectable in August 2021. The company is set to receive a huge turnover after the product is released in the global market.

Global Growth Hormone Disorder Treatment Market Scope

The global growth hormone disorder treatment market is segmented on the basis of type, disorders, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Acquired GHD
• Congenital GHD
• Idiopathic GHD
• Others

Disorders

• Small for Gestational Age (SGA)
• Short Stature
• Idiopathic Short Stature
• Turner Syndrome
• Noonan Syndrome
• Prader-Willi Syndrome
• Laron Syndrome
• Gigantism & Acromegaly
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Growth Hormone Disorder Treatment Market Regional Analysis/Insights

The global growth hormone disorder treatment market is analyzed and market size insights and trends are provided by type, disorders, distribution channel and end user as referenced above.

The major countries covered in the global growth hormone disorder treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

북미 지역은 성장 호르몬에 대한 연구개발 활동이 증가하고 의료 인프라가 잘 구축되어 있어 예측 기간 내내 글로벌 성장 호르몬 장애 치료 시장이 긍정적인 성장을 보였습니다.

아시아 태평양 지역은 기술의 급속한 발전과 만성 및 대사 질환의 유병률 증가로 인해 시장을 장악하고 있습니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 또한 글로벌 브랜드의 존재와 가용성, 그리고 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

경쟁 환경 및 글로벌 성장 호르몬 장애 치료 시장 점유율 분석

글로벌 성장 호르몬 장애 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세입니다. 제공된 위의 데이터 포인트는 글로벌 성장 호르몬 장애 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 성장 호르몬 장애 치료 시장에서 활동하는 주요 기업은 다음과 같습니다.

• Teva Pharmaceutical Industries Ltd(이스라엘)
• Amneal Pharmaceutical Inc (미국)
• Mayne Pharma Group Limited(호주)
• 머크 KGaA(독일)
• 사노피(프랑스)
• Sun Pharmaceutical Industries Ltd. (인도)
• 노바티스 AG(스위스)
• F. 호프만-라 로슈 유한회사(스위스)
• 애벗(미국)
• PT. 대웅제약(한국)
• 제넨텍 주식회사(미국)
• Bausch Health Companies Inc. (캐나다)
• 릴리(미국)
• Ipsen Pharma(프랑스)
• 페링 BV(스위스)

SKU-56109